Product image of Levonorgestrel/Ethinylestradiol Biogaran (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Levonorgestrel/Ethinylestradiol Biogaran

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Levonorgestrel/Ethinylestradiol Biogaran (Ethinylestradiol, Levonorgestrel)

Levonorgestrel/Ethinylestradiol, the active ingredient in Levonorgestrel/Ethinylestradiol Biogaran, is a combined oral contraceptive presented as a tablet for oral use. It works by preventing ovulation, thickening cervical mucus, and altering the endometrial lining to inhibit implantation, thereby providing reliable contraception for women of reproductive age.

GNH India supplies Levonorgestrel/Ethinylestradiol Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable supply chain management across global markets.

Manufacturer / TM Owner

Biogaran

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levonorgestrel/Ethinylestradiol is a combined oral contraceptive used to prevent pregnancy.

  • Prevention of pregnancy: provides reliable hormonal contraception for women of reproductive age.
  • Menstrual cycle regulation: helps achieve more predictable bleeding patterns and may reduce menstrual discomfort.
  • Treatment of hormonal acne: can improve skin condition by stabilizing androgen‑related fluctuations.

How It Works

  • Levonorgestrel/Ethinylestradiol combines an estrogen (ethinylestradiol) and a progestogen (levonorgestrel). Ethinylestradiol suppresses follicle‑stimulating hormone, inhibiting follicular development, while levonorgestrel blocks the luteinizing hormone surge, preventing ovulation. The progestogen also thickens cervical mucus and alters the endometrial lining, creating an environment unsuitable for sperm penetration and implantation.

Side Effects

Levonorgestrel/Ethinylestradiol may cause a range of adverse reactions.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: swelling or discomfort of the breasts.
  • Irregular bleeding: spotting or breakthrough bleeding between periods.

Serious or Rare Side Effects

  • Deep vein thrombosis: blood clot formation in deep veins.
  • Pulmonary embolism: clot migration to lung arteries.
  • Severe allergic reaction: hives, swelling, or anaphylaxis requiring urgent care.

Precautions & Warnings

Before prescribing Levonorgestrel/Ethinylestradiol, clinicians should consider several safety factors.

  • Assess thrombotic risk: evaluate personal and family history of clotting disorders.
  • Screen for hypertension: monitor blood pressure prior to initiation.
  • Review smoking status: avoid use in women >35 years who smoke.
  • Consider liver function: contraindicated in severe hepatic impairment.
  • Avoid in pregnancy: contraindicated during known or suspected pregnancy.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Avoid Interactions

Levonorgestrel/Ethinylestradiol can interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid)

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy.
  • Rifampin or griseofulvin: may decrease hormone levels.
  • Certain protease inhibitors (e.g., ritonavir): alter hormone metabolism.

Moderate Interactions (Monitor Closely)

  • St. John’s wort: may lower effectiveness, monitor menstrual pattern.
  • SSRIs: potential increase in mood‑related side effects.
  • Diuretics (e.g., spironolactone): may affect fluid balance and blood pressure.

Frequently Asked Questions

Levonorgestrel/Ethinylestradiol Biogaran is a combined oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It is also employed to help regulate menstrual cycles and may be prescribed for the treatment of hormonally‑related acne.

The product contains ethinylestradiol (an estrogen) and levonorgestrel (a progestogen). Ethinylestradiol suppresses follicle‑stimulating hormone, preventing follicular growth, while levonorgestrel blocks the luteinizing hormone surge, stopping ovulation. Together they thicken cervical mucus and modify the endometrial lining, creating conditions that inhibit sperm penetration and implantation.

The dosing regimen is set by the prescribing healthcare professional. Typically, a 21‑day series of active tablets is followed by a hormone‑free interval, but the exact strength, tablet count and schedule must be confirmed on the prescription label.

The combination is contraindicated in known or suspected pregnancy. While it is generally considered compatible with breastfeeding, a clinician should evaluate the individual’s risk‑benefit profile and provide guidance on any potential effects on milk production or infant exposure.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with progestogen‑only pills, the combined formulation offers more consistent cycle control and may improve acne, but it carries a slightly higher risk of estrogen‑related thrombotic events. It is usually preferred for women without contraindications to estrogen.

Store the tablets at ambient temperature, below 25 °C, in the original blister pack, protected from moisture and light. Keep the medication out of reach of children and do not use it after the printed expiration date.

The tablet is taken orally once daily, preferably at the same time each day, with or without food. A common regimen consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval during which withdrawal bleeding occurs.

Serious adverse events include venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism, arterial thrombosis leading to stroke or myocardial infarction, and severe allergic reactions like anaphylaxis. Immediate medical attention is required if symptoms of these conditions appear.

Women with a history of thromboembolic disorders, uncontrolled hypertension, current pregnancy, known or suspected breast cancer, smokers over 35 years of age, or severe liver disease should avoid this combined oral contraceptive.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.